This Week’s CGT News: Promising Data for In Vivo CAR T June 8, 2026 The Medicine Maker Share Summary Takeaways Listen Insight Report Clinical Scorecard Poll Top Institutions 1 Legend Biotech's in vivo CAR-T therapy showed promising phase 1 results, with five of six patients achieving complete response to LB2501. 2 Kelonia Therapeutics' in vivo BCMA CAR T therapy eliminated disease signs in all 18 patients with multiple myeloma one month post-treatment. 3 Induced pluripotent stem cell-derived engineered heart muscle improved heart function in patients with heart failure in a phase 1-2 study. 4 Dual CAR-T therapy enabled two end-stage kidney disease patients to receive kidney transplants by reducing harmful immune antibodies. 5 Researchers developed a method to enhance CAR T cell migration to lymph nodes, improving efficacy against B-cell malignancies in mice.
